The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Trial Parameters
Brief Summary
This is a multi-center real-world study, in which patients who meet the inclusion criteria will receive treatment with Pyrotinib + Trastuzumab + Taxanes. Taxanes will be used for 6-8 cycles or discontinued due to intolerable Adverse Events (AEs), after which Capecitabine will be used for rhythmic chemotherapy combined with Pyrotinib + Trastuzumab. The aim is to explore the efficacy and safety of Pyrotinib, Trastuzumab, and Taxanes in treating Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-70 years old, female; 2. Pathological examination confirmed HER-2 positive invasive breast cancer; (HER2 positivity is defined as an immunohistochemical (IHC) score of 3+ or in-situ hybridization (ISH) result for HER2 gene amplification in \>10% of immunoreactive cells. HER2 positivity needs to be verified by the pathology department of the research center involved in this study) 3. Imaging confirmed recurrent/metastatic breast cancer; 4. Patients who relapsed and metastasized three months after discontinuation of Trastuzumab treatment; 5. Have at least one measurable lesion (according to RECIST 1.1 criteria); 6. ECOG score of 0-2; 7. Expected life span ≥3 months; 8. Normal major organ function; 9. The researcher believes that the participant may benefit; 10. Volunteer to participate in this study, sign informed consent. Exclusion Criteria: Patients who meet any of the following criteria are not eligible for participation: 1. Have any confirmed history of